Community Health Network, GRAIL to offer Galleri MCED test in Central Indiana

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Indianapolis-based Community Health Network and GRAIL LLC have partnered to offer Galleri, GRAIL’s multi-cancer early detection blood test, to individuals at Community Health Network’s sites of care. 

Through the partnership, Community Health Network will provide the Galleri test to individuals at elevated risk for cancer, including those over the age of 50. The test will be offered to eligible individuals through their primary care providers at select Community Health Network sites as a complement to existing single cancer screenings.

In a clinical study, the Galleri test demonstrated the ability to detect a shared signal from more than 50 types of cancers. The test also determines the origin of the cancer signal.

Table of Contents

YOU MAY BE INTERESTED IN

Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, a biotechnology company developing next-generation T cell receptor-based therapies in oncology, announced that they have entered into a collaboration and license agreement to advance a novel in vivo approach to cell therapy for the treatment of solid tumors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login